Latest News & Insights
Stay Up to Date with Our Community
Featured
Latigo Biotherapeutics, Inc. (“Latigo”), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced the pricing of...
Latigo Biotherapeutics, Inc. (“Latigo”), a clinical-stage biopharmaceutical company committed to developing...
$2.5 million grant supports clinical trial activation and patient screening efforts...
Targeting clinically validated pathways to enable patients to achieve freedom from...
Recludix today announced preclinical data for REX-8756, an oral, potent and...
Star Therapeutics to receive $1.25 billion upfront, with up to $750...
Majority of patients met the American College of Rheumatology improvement criteria...
ORJ-001 achieved therapeutic exposure and was well tolerated in Phase 1...
Company announces $30 million Series A financing and founding leadership team...
Veteran biopharma leader joins to help lead Kyverna’s next phase of...